Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients
NCT04840355
·
clinicaltrials.gov ↗
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Immune Related Adverse Events
PD-1
Interventions
DRUG:
Sintilimab Injection
Sponsor
Guohui Li